Immutep to Participate in The JMP Securities Hematology and Oncology Summit
SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, will participate in The JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022.
Mr. Voigt will be available for virtual one-on-one meetings during the conference. A live webcast of his presentation will be available here and after the meting under the Events page within the Investors & Media section of Immutep’s website.
Immutep’s lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.
Further information can be found on the Company’s website www.immutep.com or by contacting:
Keynote Address by IT Complete, A Kaseya Company: Global State Of The MSP and What it Means to the Market
Session Details TBA
IoT Evolution Expo #TECHSUPERSHOW Expo Hall Grand Opening